Acceleron Appoints Global Innovation and Drug Development Executive Kemal Malik, MB BS, to its Board of Directors
06 Diciembre 2019 - 7:00AM
Business Wire
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical
company in the discovery and development of TGF-beta superfamily
therapeutics to treat serious and rare diseases, announced today
the appointment of Kemal Malik, MB BS, to its Board of Directors.
Dr. Malik, who is currently a member of the Board of Management of
Bayer AG, will officially join the Acceleron Board effective
January 1, 2020.
“We’re thrilled to be able to add an individual of Kemal’s
caliber to the Acceleron Board,” said Francois Nader, M.D.,
Chairman of Acceleron Pharma. “His global development and
innovation experience across a range of therapeutic areas should
prove enormously valuable in helping to guide Acceleron through its
exciting transition from a clinical-stage organization to a
fully-integrated biopharmaceutical company.”
Dr. Malik has served on the Board of Management of Bayer AG
since 2014, with responsibility for Innovation across the Bayer
group. His career at Bayer began in 1995 as Head of Metabolic
Medicine and Oncology for Europe. He later served as Head of Global
Medical Development, before being appointed in 2004 as Head of
Global Development and Chief Medical Officer as well as a member of
the Executive Committee of Bayer HealthCare AG. Dr. Malik received
his medical qualification from the University of London.
“It’s a privilege to join the Board of Acceleron,” said Dr.
Malik. “Having spent considerable time pursuing innovation at
Bayer, I’m delighted to be associated with a company dedicated to
delivering first-in-class approaches to patients who have long been
in need of new therapeutic options.”
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to
treat serious and rare diseases. The Company's leadership in the
understanding of TGF-beta superfamily biology and protein
engineering generates innovative compounds that engage the body's
ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in
hematologic, neuromuscular, and pulmonary diseases. In hematology,
the Company and its global collaboration partner, Bristol-Myers
Squibb, are co-promoting newly approved REBLOZYL®
(luspatercept-aamt), the first and only approved erythroid
maturation agent, in the United States and are developing
luspatercept for the treatment of chronic anemia in myelodysplastic
syndromes and myelofibrosis. Acceleron is also advancing its
neuromuscular program with ACE-083, a locally-acting Myostatin+
agent in Phase 2 development in Charcot-Marie-Tooth disease and is
conducting a Phase 2 pulmonary program with sotatercept in
pulmonary arterial hypertension.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social Media: @AcceleronPharma and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191206005054/en/
Acceleron Pharma Inc.
Investors: Todd James, IRC, 617-649-9393 Vice President, Investor Relations
and Corporate Communications
Ed Joyce, 617-649-9242 Director,
Investor Relations
Media: Matt Fearer, 617-301-9557
Director, Corporate Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024